[Killing effect of 131I-Herceptin on breast cancer cell lines in vitro].
OBJECTIVE
To study the specific killing effect of (131)I-labeled Herceptin on breast cancer cell lines positive for Her-2 expression.


METHODS
Anti-Her-2 monoclonal antibody Herceptin was labeled with (131)I by means of IODO-GEN, and the killing effects of Herceptin on SK-BR-3, MCF-7 and A549 cell lines expressing Her-2 were evaluated with MTT assay.


RESULTS
(131)I-Herceptin had immunoactivity had to that of Herceptin but possessed stronger killing effects on the cell lines expressing Her-2 than Herceptin and (131)I used alone (P<0.05). Its killing effect on cell lines negative or only weakly positive for Her-2 expression was similar to that of (131)I and Herceptin.


CONCLUSIONS
(131)I-Herceptin can specifically kill Her-2-positive cancer cells in vitro.
Lin
Jing
J
Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Luo
Rong-cheng
RC
Li
Ai-min
AM
Zhang
Jun-yi
JY
Lü
Cheng-wei
CW
Yan
Xiao
X
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000494:pharmacology; D007457:Iodine Radioisotopes / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000187:drug effects*; D000068878:Trastuzumab; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000922:Immunotoxins; D007457:Iodine Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab